Literature DB >> 33392023

18F-FDG PET-based radiomics model for predicting occult lymph node metastasis in clinical N0 solid lung adenocarcinoma.

Lili Wang1, Tiancheng Li2, Junjie Hong1, Mingyue Zhang3, Mingli Ouyang4, Xiangwu Zheng1, Kun Tang1.   

Abstract

BACKGROUND: This study aimed to develop a preoperative positron emission tomography (PET)-based radiomics model for predicting occult lymph node metastasis (OLM) in clinical N0 (cN0) solid lung adenocarcinoma.
METHODS: The preoperative fluorine-18-fludeoxyglucose (18F-FDG) PET images of 370 patients with cN0 lung adenocarcinoma confirmed by histopathological examination were retrospectively reviewed. Patients were divided into training and validation sets. Radiomics features and relevant data were extracted from PET images. A nomogram was developed in a training set via univariate and multivariate logistic analyses, and its performance was assessed by concordance-index (C-index), calibration curves, and decision curve analysis (DCA) in the training and validation sets.
RESULTS: The multivariate logistic regression analysis showed that only carcinoembryonic antigen (CEA), metabolic tumor volume (MTV), and the radiomics signature had statistically significant differences between patients with and without OLM (P<0.05). A nomogram was developed based on the logistic analyses, and its C-index was 0.769 in the training set and 0.768 in the validation set. The calibration curve demonstrated good consistency between the nomogram-predicted probability of OLM and the actual rate. The DCA also confirmed the clinical utility of the nomogram.
CONCLUSIONS: A PET/computed tomography (CT)-based radiomics model including CEA, MTV, and the radiomics signature was developed and demonstrated adequate predictive accuracy and clinical net benefit in the present study, and was conveniently used to facilitate the individualized preoperative prediction of OLM. 2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Lung adenocarcinoma; diagnosis; lymph node; positron emission tomography radiomics (PET radiomics); positron emission tomography/computed tomography (PET/CT)

Year:  2021        PMID: 33392023      PMCID: PMC7719913          DOI: 10.21037/qims-20-337

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  42 in total

1.  Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT.

Authors:  Ming-Li Ouyang; Hu-Wei Xia; Man-Man Xu; Jie Lin; Li-Li Wang; Xiang-Wu Zheng; Kun Tang
Journal:  Ann Nucl Med       Date:  2019-06-10       Impact factor: 2.668

2.  Development and validation of a radiomics nomogram for identifying invasiveness of pulmonary adenocarcinomas appearing as subcentimeter ground-glass opacity nodules.

Authors:  Wei Zhao; Ya'nan Xu; Zhiming Yang; Yingli Sun; Cheng Li; Liang Jin; Pan Gao; Wenjie He; Peijun Wang; Hongli Shi; Yanqing Hua; Ming Li
Journal:  Eur J Radiol       Date:  2019-01-22       Impact factor: 3.528

3.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

4.  Sublobar resection is associated with better perioperative outcomes in elderly patients with clinical stage I non-small cell lung cancer: a multicenter retrospective cohort study.

Authors:  Zhenrong Zhang; Hongxiang Feng; Heng Zhao; Jian Hu; Lunxu Liu; Yang Liu; Xiaofei Li; Lin Xu; Yin Li; Xike Lu; Xiangning Fu; Haiying Yang; Deruo Liu
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

5.  A new approach to predict lymph node metastasis in solid lung adenocarcinoma: a radiomics nomogram.

Authors:  Xinguan Yang; Xiaohuan Pan; Hui Liu; Dashan Gao; Jianxing He; Wenhua Liang; Yubao Guan
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 6.  Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art.

Authors:  Geewon Lee; Ho Yun Lee; Hyunjin Park; Mark L Schiebler; Edwin J R van Beek; Yoshiharu Ohno; Joon Beom Seo; Ann Leung
Journal:  Eur J Radiol       Date:  2016-09-10       Impact factor: 3.528

7.  18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.

Authors:  Sara Carvalho; Ralph T H Leijenaar; Esther G C Troost; Janna E van Timmeren; Cary Oberije; Wouter van Elmpt; Lioe-Fee de Geus-Oei; Johan Bussink; Philippe Lambin
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

8.  Occult mediastinal lymph node metastasis in FDG-PET/CT node-negative lung adenocarcinoma patients: Risk factors and histopathological study.

Authors:  Huang Miao; Li Shaolei; Li Nan; Lai Yumei; Zhang Shanyuan; Lu Fangliang; Yang Yue
Journal:  Thorac Cancer       Date:  2019-05-24       Impact factor: 3.500

9.  Radiomics prediction model for the improved diagnosis of clinically significant prostate cancer on biparametric MRI.

Authors:  Mengjuan Li; Tong Chen; Wenlu Zhao; Chaogang Wei; Xiaobo Li; Shaofeng Duan; Libiao Ji; Zhihua Lu; Junkang Shen
Journal:  Quant Imaging Med Surg       Date:  2020-02

10.  Radiomics: Images Are More than Pictures, They Are Data.

Authors:  Robert J Gillies; Paul E Kinahan; Hedvig Hricak
Journal:  Radiology       Date:  2015-11-18       Impact factor: 11.105

View more
  8 in total

1.  Bronchial morphological changes are associated with postoperative intractable cough after right upper lobectomy in lung cancer patients.

Authors:  Xue-Fang Lu; Xin-Ping Min; Biao Lu; Guo-Hua Fan; Tie-Yuan Zhu
Journal:  Quant Imaging Med Surg       Date:  2022-01

2.  Risk analysis in peripheral clinical T1 non-small cell lung cancer correlations between tumor-to-blood standardized uptake ratio on 18F-FDG PET-CT and primary tumor pathological invasiveness: a real-world observational study.

Authors:  Xiao-Feng Li; Yun-Mei Shi; Rong Niu; Xiao-Nan Shao; Jian-Feng Wang; Xiao-Liang Shao; Fei-Fei Zhang; Yue-Tao Wang
Journal:  Quant Imaging Med Surg       Date:  2022-01

3.  Identifying 18F-FDG PET-metabolic radiomic signature for lung adenocarcinoma prognosis via the leveraging of prognostic transcriptomic module.

Authors:  Jin Li; Yixin Liu; Wenlei Dong; Yang Zhou; Jingquan Wu; Kuan Luan; Lishuang Qi
Journal:  Quant Imaging Med Surg       Date:  2022-03

4.  18F-FDG PET/CT radiomics nomogram for predicting occult lymph node metastasis of non-small cell lung cancer.

Authors:  Jianyi Qiao; Xin Zhang; Ming Du; Pengyuan Wang; Jun Xin
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

Review 5.  Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.

Authors:  David Morland; Elizabeth Katherine Anna Triumbari; Luca Boldrini; Roberto Gatta; Daniele Pizzuto; Salvatore Annunziata
Journal:  Diagnostics (Basel)       Date:  2022-05-27

6.  Development and Validation of a 18F-FDG PET-Based Radiomic Model for Evaluating Hypermetabolic Mediastinal-Hilar Lymph Nodes in Non-Small-Cell Lung Cancer.

Authors:  Ming-Li Ouyang; Yi-Ran Wang; Qing-Shan Deng; Ye-Fei Zhu; Zhen-Hua Zhao; Ling Wang; Liang-Xing Wang; Kun Tang
Journal:  Front Oncol       Date:  2021-09-08       Impact factor: 6.244

7.  Predictive Value of 18F-FDG PET/CT-Based Radiomics Model for Occult Axillary Lymph Node Metastasis in Clinically Node-Negative Breast Cancer.

Authors:  Kun Chen; Guotao Yin; Wengui Xu
Journal:  Diagnostics (Basel)       Date:  2022-04-15

8.  Deep Learning Analysis Using 18F-FDG PET/CT to Predict Occult Lymph Node Metastasis in Patients With Clinical N0 Lung Adenocarcinoma.

Authors:  Ming-Li Ouyang; Rui-Xuan Zheng; Yi-Ran Wang; Zi-Yi Zuo; Liu-Dan Gu; Yu-Qian Tian; Yu-Guo Wei; Xiao-Ying Huang; Kun Tang; Liang-Xing Wang
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.